The weight-loss drug landscape is rapidly shifting from injections to pills. And this time, it may not be Novo Nordisk (NVO) leading the charge—it could be Eli Lilly (LLY).
Last year, Novo Nordisk was first to market with an oral version of Wegovy, aiming to lock down its share of the obesity market with a more convenient formulation. But that first-mover advantage may be short-lived. Eli Lilly’s oral GLP-1 candidate, Orforglipron, is on track for approval as early as the second quarter of this year. With greater dosing flexibility and broader label potential, the drug could cement Lilly’s dominance in the weight-loss space—and potentially become the next blockbuster generating tens of billions in annual sales.
In January, Novo Nordisk launched oral Wegovy, the first oral GLP-1 approved for chronic weight management. For patients averse to injections, it marked a significant step forward.
Early market feedback has been positive. But the product’s “technical moat” may not be as deep as it seems. Oral Wegovy comes with strict dosing requirements: it must be taken first thing in the morning on an empty stomach, and patients must wait at least 30 minutes before eating or drinking. While that may sound minor, in real-world use, it could deter a meaningful portion of patients seeking simplicity and flexibility.
Perhaps more importantly, oral Wegovy is currently approved only for weight loss—not for diabetes. That means Novo Nordisk’s oral offering doesn’t yet address the vast type 2 diabetes population, leaving a significant gap in coverage.
Once approved, Orforglipron is expected to enter the market with three distinct advantages that could quickly challenge Novo’s early lead.
First, greater convenience. Orforglipron requires no food or beverage restrictions. Patients can take it at any time of day, regardless of meals. For those with busy schedules or difficulty adhering to strict fasting requirements, this is a major differentiator. Novo Nordisk itself has noted that oral Wegovy is effectively “expanding the market”—drawing in patients who previously avoided injectables. With better compliance potential, Orforglipron is well positioned to capture a larger share of that new patient pool.
Second, dual indication potential. Orforglipron has been submitted for approval not only for weight management, but also for type 2 diabetes. That means it could go head-to-head with Novo Nordisk’s other oral GLP-1, Rybelsus. Clinical data show Orforglipron outperformed Rybelsus in reducing A1C levels, while also delivering strong weight-loss benefits in diabetic patients. This dual efficacy profile could give it a clear edge in physician prescribing decisions.
Third, supply is ready. Supply constraints have plagued the weight-loss drug market, with both Novo Nordisk and Lilly facing shortages of their injectable products. This time, Lilly appears to be preparing for a different outcome. The company has already built an inventory worth approximately $1.5 billion and stated that it expects to begin shipping within a week of approval. That level of readiness will allow Lilly to capture market share rapidly, leaving little room for competitors to respond.
Lilly has already established a strong foothold in the weight-loss market with Zepbound. Orforglipron, if approved, would further deepen that moat.
But Orforglipron is just one piece of a much larger metabolic disease pipeline. Retatrutide, the company’s first-in-class triple hormone receptor agonist, posted strong Phase 2 results last year. If development continues on track, Lilly could soon offer a full spectrum of treatments—from single-target to multi-target, from injectable to oral.
Analysts expect the global anti-obesity drug market to grow rapidly in the coming years. In this race, Lilly not only holds a leading position today, but its pipeline depth and breadth also leave competitors struggling to keep pace.
For investors, Lilly’s performance over the past five years has already been remarkable. But with the obesity market still in its early stages and new products like Orforglipron on the horizon, the company may have room to deliver further upside. When a drug offers better convenience, broader indications, and ready supply—all at once—it may be just one approval away from becoming the next king of the market.
